Core Viewpoint - The company has issued a positive profit forecast, expecting a net profit exceeding RMB 240 million in 2025, representing a year-on-year growth of approximately 139.4%, with revenue anticipated to exceed RMB 1.05 billion, a year-on-year increase of about 34.6% [1][2]. Performance Overview - The company is set to release its audited annual report soon, likely before March 2026, following the positive earnings announcement [2]. Business Development - In January 2026, the company announced a strategic acquisition of the German company Optimed to accelerate its penetration into the European market. By the end of 2025, its sales channels had expanded to cover 83 countries, with overseas revenue growing by over 100% year-on-year. Future focus will be on the synergies from the acquisition, overseas regulatory approvals, and progress in new market expansions [3]. Product Development - The sales performance of products such as the Qianqiao Qilin blood flow guiding device and ZYLOX Swan venous catheter was strong in 2025. Additionally, innovative products like the carotid double-layer mesh stent have entered the "green channel" of the National Medical Products Administration. The approval of new products and the volume of existing products in a centralized procurement environment may become market focal points [4]. Stock Performance - Following the positive earnings forecast and internationalization progress, the company's stock price rose nearly 7% on February 3, 2026, with a trading volume of HKD 17.88 million. If the official earnings report exceeds expectations or new developments in strategic layout emerge, it may further influence short-term market sentiment [5].
归创通桥2025年业绩预喜，净利润预计大增近140%